Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX.

We applied Systematic Evolution of Ligands by EXponential enrichment using Small Cell Lung Cancer (SCLC) cells. A DNA aptamer was identified and evaluated by fluorescent confocal microscopy and flow cytometry. Our results showed that the DNA aptamer binds to molecules that exist predominantly on target SCLC cell surfaces compared with other types of SCLC cells.

[1]  Xiaohong Fang,et al.  Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. , 2009, The Analyst.

[2]  Weihong Tan,et al.  Identification of liver cancer-specific aptamers using whole live cells. , 2008, Analytical chemistry.

[3]  Ioanis Katakis,et al.  Aptamers: molecular tools for analytical applications , 2008, Analytical and bioanalytical chemistry.

[4]  A. Price,et al.  International comparisons of survival from lung cancer: pitfalls and warnings , 2007, Nature Clinical Practice Oncology.

[5]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[6]  Weihong Tan,et al.  Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers , 2008, ChemMedChem.

[7]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[8]  Ravi Salgia,et al.  Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. , 2007, Mass spectrometry reviews.

[9]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[10]  J. Winter,et al.  A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells , 2003, Cancer Immunology, Immunotherapy.

[11]  J. Minna,et al.  Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? , 2010, Lung cancer.

[12]  K. Yamaguchi,et al.  Proneurotensin/neuromedin N secreted from small cell lung carcinoma cell lines as a potential tumor marker , 2008, Proteomics. Clinical applications.